Subscribe To
Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...
October 25, 2023, 9:26 pm
Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...
October 25, 2023, 9:26 pm
Sanford heisler sharp adds brent hannafan, criminal chief of the u.s. attorney’s office for the middle district of tennessee
Joins National Office of National Civil Rights Firmbecomes Firm’s Trial Practice Co-Chair NASHVILLE, ...
June 22, 2023, 2:05 pm
Fda advisory committee votes unanimously to confirm the clinical benefit of leqembi® (lecanemab-irmb) for the treatment of alzheimer’s disease
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in...
June 9, 2023, 10:45 pm
Fda accepts eisai’s filing of a supplemental biologics license application and grants priority review for traditional approval of leqembi™ (lecanemab-irmb) for the treatment of alzheimer’s disease
Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approva...
March 5, 2023, 11:30 pm
